KRSouth Korea
Korea obesity drug prices come under pressure as a new carry in rule opens the door to cheaper pens from Japan
Korea now lets patients bring home prescribed Mounjaro and Wegovy bought abroad, and lawmaker data put the Korean supply price of the starting Mounjaro pen at 5.1 times the Japanese one. Lilly says the markets cannot be compared.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itA new rule letting Koreans carry home prescribed obesity drugs bought abroad, plus data showing a 5.1 times supply price gap with Japan, adds pressure on Mounjaro and Wegovy prices in Korea.
Korea obesity drug prices are under new pressure after a customs change let patients bring home prescribed medicines bought abroad. Since 12 November, travellers may carry in drugs such as Mounjaro and Wegovy when a foreign regulator approved them and a doctor there prescribed them. Prices in Japan and China run well below Korean levels, and figures released by a lawmaker put the Korean supply price of the starting Mounjaro pen at about five times the Japanese one. Eli Lilly says the gap reflects different insurance systems, and no company has cut its price so far.
What the new carry in rule allows
The Ministry of Food and Drug Safety announced the change on 11 November after talks with the Korea Customs Service, and it took effect the next day, the Korea JoongAng Daily reported. A person may now bring in up to six bottles of a medicine for their own treatment, or more when the amount stays within three months of use under the prescribing instructions. For a weekly single-use injection such as Mounjaro the cap works out at twelve doses. Two conditions apply: the medicine must hold approval from the regulator of the country where it was obtained, and it must have been bought on a prescription. The rule also covers Koreans returning with leftover doses of a medicine first prescribed at home, and foreign students and tourists.
The change answers a run of complaints that the state was blocking medicines that patients had obtained legally abroad. Obesity drugs had become the clearest case because the price gap with Japan is so wide. Business daily Money Today, in an English edition of a report on obesity drug pricing, said patients are now looking for prescriptions in Japan and China and judge the trip worth it even after flights and hotels. The rule does not make overseas online orders legal, and it gives no route for products that lack a foreign approval. Korea already has Mounjaro approved by its own regulator, so the issue is cost, not access to the molecule itself.
How far apart the prices are
Several sets of figures point the same way. Money Today wrote that a four-week supply of a higher Mounjaro strength sells for around 500,000 won in Korea, against about 300,000 won in Japan with insurance and close to 200,000 won in China. The JoongAng Daily put a four-week course of the starting strength at roughly 280,000 to 350,000 won in Korea and 80,000 to 120,000 won at some Japanese clinics. The sharpest number comes from Nam In-soon, a Democratic Party member of the National Assembly health and welfare committee. Using data from the National Health Insurance Service and the Health Insurance Review and Assessment Service, she showed a Korean ex-factory price of 68,397 won for the starting Mounjaro pen in the first half of the year.
The sharpest number comes from Nam In-soon, a Democratic Party member of the National Assembly health and welfare committee.
The comparable Japanese supply price in her data was 13,340 won, so the Korean figure is about 5.1 times higher. Supply prices are what the maker charges before pharmacy and clinic margins, which is why they sit far below what patients pay at the counter. They are still the cleanest like for like measure, because retail prices in both countries vary by clinic and by how much the doctor's fee adds. The table sets out the numbers in the reports. Japanese patients in the reported cases pay with insurance, while in Korea obesity drugs are not yet covered and Wegovy is still under reimbursement review, which partly explains the Lilly view that the two markets cannot be compared directly.
| Measure | Korea | Japan | China | Source |
|---|---|---|---|---|
| Starting Mounjaro pen, ex-factory supply price, first half of 2026 | 68,397 won | 13,340 won | Not given | Nam In-soon, from NHIS and HIRA data |
| Four weeks of a higher Mounjaro strength, patient price | About 500,000 won | About 300,000 won with insurance | About 200,000 won | Money Today |
| Four weeks of the starting strength, patient price | 280,000 to 350,000 won | 80,000 to 120,000 won at some clinics | Not given | Korea JoongAng Daily |
| Four weeks of Hanmi Epe at its starting step, supply price | 129,800 won | Not sold | Not sold | Money Today |
Korea obesity drug prices and the local challenger
Price pressure is also coming from inside the market. Hanmi Pharmaceutical's Epe, the domestic GLP-1 drug the company recently brought to market, has a four-week supply price at its starting step of 129,800 won, Money Today reported, which is about half of the roughly 270,000 won supply price for four low-strength Mounjaro pens. Peptide Global covered how the Epe launch undercut Mounjaro on its starting price. A cheaper local option changes the bargaining position of patients and clinics, and it gives payers and lawmakers a reference point when they question import prices. Korea obesity drug prices have so far been set by two global brands, and Epe is the first serious domestic alternative at a lower level.
More competition is queued. Eli Lilly has applied to the Ministry of Food and Drug Safety to approve Foundayo, its oral GLP-1 drug orforglipron, and Novo Nordisk has filed its Wegovy tablet, according to Money Today. Both are already sold in the United States. Tablets are usually priced below injections, and their arrival could widen the spread of options in Korea. Demand is already broad: a recent survey found that one in ten Korean adults had used or been prescribed a GLP-1 obesity drug in the past year, with the highest use among Gen Z. That makes cost a question for a large group of private payers rather than a small group of patients.
What Lilly says and what to watch
No maker has moved its price yet, Money Today found. A Lilly official told the paper that "the drug price difference between Korea and Japan reflects fundamentally different national health insurance systems and cannot be simply compared." The official added that Lilly is "exploring various ways to ensure domestic patients who need Mounjaro can access treatment," a general line with no figure or date attached. The report carried no comment from Novo Nordisk. Pressure on Korea obesity drug prices therefore comes from three places at once: patients who can now legally carry medicine home, a domestic rival priced lower, and lawmakers who have put the supply gap with Japan into the public record.
The next points to watch are concrete. One is whether the customs change leads to measurable volumes of Mounjaro and Wegovy entering through airports, which the customs service could report. Another is how the Ministry of Food and Drug Safety handles the two oral filings and what prices Lilly and Novo set if those tablets are approved. A third is whether the health committee uses the Nam In-soon data to push for price talks or for insurance coverage of obesity drugs, which Korea has not yet granted. Until one of those moves happens, the price gap stays a matter for individual patients weighing a flight against a local prescription.
Conclusion
Korea obesity drug prices now face an outside benchmark that patients can reach legally. The carry in rule from 12 November, a supply price gap of about five times with Japan and a cheaper domestic rival in Epe all point toward lower prices, but Lilly has made no change and calls the comparison unfair. The tests ahead are the customs data, the oral GLP-1 decisions and any move by lawmakers.
Why it matters in South Korea
Obesity drugs are not yet covered by national insurance in Korea, so patients feel the full price. Japan and China sell the same pens for far less, and from 12 November patients may legally bring them home with a foreign prescription.
What to watch
Customs data on carried-in volumes, MFDS decisions and prices for the Foundayo and Wegovy tablets, and whether the National Assembly health committee pushes for price talks.
Sources
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.